Evolent Health, Inc. (NYSE:EVH) Given Average Rating of “Buy” by Brokerages

Shares of Evolent Health, Inc. (NYSE:EVH) have earned a consensus recommendation of “Buy” from the fourteen ratings firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, twelve have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $17.71.

Several research analysts have recently commented on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $15.00 price target on shares of Evolent Health in a report on Friday, February 21st. Canaccord Genuity Group decreased their target price on Evolent Health from $23.00 to $16.00 and set a “buy” rating for the company in a research note on Thursday, January 23rd. JMP Securities reaffirmed a “market outperform” rating and set a $13.00 target price on shares of Evolent Health in a report on Monday. Oppenheimer cut their price target on Evolent Health from $28.00 to $18.00 and set an “outperform” rating on the stock in a report on Friday, January 24th. Finally, Citigroup lowered their price objective on Evolent Health from $21.00 to $18.00 and set a “buy” rating for the company in a research note on Friday, January 10th.

Evolent Health Trading Up 5.5 %

NYSE:EVH opened at $9.85 on Wednesday. The company has a market cap of $1.15 billion, a PE ratio of -12.01 and a beta of 1.20. The business’s 50 day moving average is $9.49 and its two-hundred day moving average is $12.36. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.58. Evolent Health has a 52 week low of $8.35 and a 52 week high of $33.63.

Evolent Health (NYSE:EVH) last announced its quarterly earnings data on Thursday, February 20th. The technology company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.38 by ($0.35). The firm had revenue of $646.54 million for the quarter, compared to the consensus estimate of $650.92 million. Evolent Health had a positive return on equity of 5.73% and a negative net margin of 2.41%. On average, analysts predict that Evolent Health will post 0.08 EPS for the current year.

Insider Activity at Evolent Health

In related news, Director Diane Holder acquired 2,735 shares of the stock in a transaction that occurred on Thursday, March 6th. The shares were acquired at an average price of $9.33 per share, for a total transaction of $25,517.55. Following the completion of the purchase, the director now directly owns 70,584 shares of the company’s stock, valued at $658,548.72. The trade was a 4.03 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Seth Blackley bought 55,225 shares of the business’s stock in a transaction on Thursday, March 6th. The stock was purchased at an average price of $9.01 per share, with a total value of $497,577.25. Following the completion of the transaction, the chief executive officer now directly owns 762,217 shares of the company’s stock, valued at $6,867,575.17. This trade represents a 7.81 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased a total of 74,000 shares of company stock worth $666,315 over the last ninety days. 1.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Pilgrim Partners Asia Pte Ltd bought a new stake in Evolent Health in the fourth quarter worth about $26,000. R Squared Ltd bought a new stake in shares of Evolent Health in the 4th quarter worth approximately $31,000. AlphaQuest LLC lifted its stake in Evolent Health by 21,650.0% during the fourth quarter. AlphaQuest LLC now owns 3,045 shares of the technology company’s stock valued at $34,000 after purchasing an additional 3,031 shares during the last quarter. Parkside Financial Bank & Trust boosted its holdings in Evolent Health by 90.7% during the fourth quarter. Parkside Financial Bank & Trust now owns 4,957 shares of the technology company’s stock worth $56,000 after buying an additional 2,358 shares in the last quarter. Finally, AlphaCentric Advisors LLC acquired a new position in Evolent Health in the fourth quarter worth approximately $61,000.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.